BR112022015803A2 - Composto, partícula lipídica, composição, composição farmacêutica, métodos para a distribuição in vivo de um agente terapêutico, para tratar uma doença e para distribuir um agente terapêutico e uso de uma partícula lipídica - Google Patents

Composto, partícula lipídica, composição, composição farmacêutica, métodos para a distribuição in vivo de um agente terapêutico, para tratar uma doença e para distribuir um agente terapêutico e uso de uma partícula lipídica

Info

Publication number
BR112022015803A2
BR112022015803A2 BR112022015803A BR112022015803A BR112022015803A2 BR 112022015803 A2 BR112022015803 A2 BR 112022015803A2 BR 112022015803 A BR112022015803 A BR 112022015803A BR 112022015803 A BR112022015803 A BR 112022015803A BR 112022015803 A2 BR112022015803 A2 BR 112022015803A2
Authority
BR
Brazil
Prior art keywords
therapeutic agent
lipid particle
composition
distributing
disease
Prior art date
Application number
BR112022015803A
Other languages
English (en)
Portuguese (pt)
Inventor
Heyes James
Mong Lam Kieu
J Holland Richard
Zhang Wenxuan
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of BR112022015803A2 publication Critical patent/BR112022015803A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022015803A 2020-02-11 2021-02-11 Composto, partícula lipídica, composição, composição farmacêutica, métodos para a distribuição in vivo de um agente terapêutico, para tratar uma doença e para distribuir um agente terapêutico e uso de uma partícula lipídica BR112022015803A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975116P 2020-02-11 2020-02-11
PCT/US2021/017676 WO2021163339A1 (en) 2020-02-11 2021-02-11 Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells

Publications (1)

Publication Number Publication Date
BR112022015803A2 true BR112022015803A2 (pt) 2022-10-11

Family

ID=77292598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015803A BR112022015803A2 (pt) 2020-02-11 2021-02-11 Composto, partícula lipídica, composição, composição farmacêutica, métodos para a distribuição in vivo de um agente terapêutico, para tratar uma doença e para distribuir um agente terapêutico e uso de uma partícula lipídica

Country Status (11)

Country Link
US (1) US20230139594A1 (https=)
EP (1) EP4103172A4 (https=)
JP (1) JP7843707B2 (https=)
KR (1) KR20220140531A (https=)
CN (1) CN115697321A (https=)
AU (1) AU2021218409A1 (https=)
BR (1) BR112022015803A2 (https=)
CA (1) CA3170547A1 (https=)
IL (1) IL295441A (https=)
MX (1) MX2022009861A (https=)
WO (1) WO2021163339A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
CN117045791B (zh) * 2023-03-22 2025-10-03 中国药科大学 肝星状细胞neu1的靶向过表达剂在制备治疗肝纤维化的药物中的应用
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
JP2025168864A (ja) * 2024-04-30 2025-11-12 信越化学工業株式会社 含窒素多官能オルガノキシシラン化合物の製造方法
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB709345A (en) * 1950-08-28 1954-05-19 California Research Corp Unsymmetrical alkoxy (tri- and tetra-) siloxanes and processes for making the same
US2713064A (en) * 1953-12-07 1955-07-12 Dow Corning Bis-(trialkoxysilyl) benzenes and their use
US3029269A (en) * 1956-08-21 1962-04-10 California Research Corp Silicon esters
DE1180359B (de) * 1962-05-15 1964-10-29 Ruhrchemie Ag Verfahren zur kontinuierlichen Herstellung von Orthokieselsaeureestern
NL134718C (https=) * 1966-12-01
US3810843A (en) * 1971-05-28 1974-05-14 Gen Electric Silicone-silica compositions
CH632765A5 (de) * 1977-09-09 1982-10-29 Ciba Geigy Ag Verfahren zur herstellung von siliciummodifizierten phthalsaeurederivaten.
US4329486A (en) * 1981-06-29 1982-05-11 Olin Corporation Process for preparing alkoxysilane cluster compounds by reacting a trialkoxysilanol with an amidated alkoxysilane cluster compound
JPH086040B2 (ja) * 1990-10-26 1996-01-24 信越化学工業株式会社 オルガノポリシロキサン組成物
US5534592A (en) * 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
EP1687830B1 (en) * 2003-11-28 2010-07-28 Merck Patent GmbH Organic semiconducting layer formulations comprising polyacenes and organic binder polymers
JP5401316B2 (ja) * 2006-09-29 2014-01-29 モメンティブ パフォーマンス マテリアルズ インコーポレイテッド 加水分解性有機官能性シランの部分および／または完全縮合物の貯蔵に安定な組成物
JP5316743B2 (ja) * 2007-11-01 2013-10-16 Ｊｓｒ株式会社 ケイ素含有膜形成用組成物およびケイ素含有絶縁膜の形成方法
JP5133092B2 (ja) 2008-03-06 2013-01-30 花王株式会社 機能性物質放出剤
CN101724127A (zh) * 2008-10-16 2010-06-09 住友橡胶工业株式会社 聚合物、橡胶组合物及使用该橡胶组合物的轮胎
US9375484B2 (en) 2011-05-31 2016-06-28 Regents Of The University Of Minnesota Taxane silicate prodrugs and nanoparticles
CN102911401B (zh) 2012-11-08 2014-04-23 广州市回天精细化工有限公司 一种羟基清除剂、其制备方法及含有它的硫化硅橡胶
JP6614014B2 (ja) * 2016-04-26 2019-12-04 信越化学工業株式会社 含窒素オルガノキシシラン化合物およびその製造方法
DE102017221259A1 (de) * 2017-11-28 2019-05-29 Evonik Degussa Gmbh Silanmischungen und Verfahren zu deren Herstellung
JP6865898B2 (ja) * 2017-12-21 2021-04-28 スリーエム イノベイティブ プロパティズ カンパニー シラン処理された表面を有する歯科用無機充填剤
CN108239103B (zh) 2018-01-02 2020-09-01 深圳市广业电子科技有限公司 一种含有多肟基硅的硅氮化合物
CA3105394A1 (en) * 2018-07-02 2020-01-09 Aptamir Therapeutics, Inc. Targeted delivery of therapeutic agents to human adipocytes
AU2021403156A1 (en) * 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles

Also Published As

Publication number Publication date
JP2023513698A (ja) 2023-04-03
NZ791587A (en) 2025-06-27
CA3170547A1 (en) 2021-08-19
EP4103172A1 (en) 2022-12-21
WO2021163339A1 (en) 2021-08-19
EP4103172A4 (en) 2024-05-01
JP7843707B2 (ja) 2026-04-10
IL295441A (en) 2022-10-01
US20230139594A1 (en) 2023-05-04
MX2022009861A (es) 2022-11-07
AU2021218409A1 (en) 2022-09-22
KR20220140531A (ko) 2022-10-18
CN115697321A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
BR112022015803A2 (pt) Composto, partícula lipídica, composição, composição farmacêutica, métodos para a distribuição in vivo de um agente terapêutico, para tratar uma doença e para distribuir um agente terapêutico e uso de uma partícula lipídica
Kumar Lipid-based nanoparticles for drug-delivery systems
Heo et al. Inhibition of osteoclast differentiation by gold nanoparticles functionalized with cyclodextrin curcumin complexes
Bastiancich et al. Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment
Wang et al. Formulation and characterization of a 3D-printed cryptotanshinone-loaded niosomal hydrogel for topical therapy of acne
ZA202103233B (en) Lipid nanoparticle formulations
BR112014027834A2 (pt) composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
Kroon et al. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo
MX2024011629A (es) Lípidos ionizables y nanopartículas lípidicas novedosos y métodos para usarlos
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
CL2013003621A1 (es) Composición farmacéutica inhalable que comprende una dispersión de partículas liposomales que contienen un agente bioactivo hidrófobo, tal como coq10, un fosfolípido, y un vehículo de dispersión acuosa, apta para aerosolización continua; método de preparación; método de administración; uso para tratar enfermedades del pulmón.
GB0814302D0 (en) Compounds and methods
BR112015022432A2 (pt) microestrutura de matriz para a entrega de agentes ativos
MX2009012279A (es) Distribucion de micro y nanoparticulas con plaquetas.
Sylvester et al. Nanoparticles for localized delivery of hyaluronan oligomers towards regenerative repair of elastic matrix
CY1119805T1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
WO2021188389A3 (en) Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
CL2023001639A1 (es) Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
SA517390331B1 (ar) تراكيب مصفوفة بوليمر موضعية تشتمل على تركيز عالي من هيالورونات الصوديوم المخمر حيوياً واستخداماتها
Tamane et al. Exploring the potential of site-specific co-delivery of Berberine alongside 5-fluorouracil in oral cancer: Formulation development, in-vitro apoptosis, ex-vivo permeability and in-vivo biocompatibility studies
Wang et al. Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]